Telluris Biotech: Financial Breakdown
Decoding financial health metrics of Telluris Biotech
Total Revenue₹23.3 Lakh-82%Prev. FY
Total Expenses₹6.8 Cr-11%Prev. FY
Profit After Tax₹-6.9 Cr-11%Prev. FY
Total Assets₹15.5 Cr-2%Prev. FY
Net Profit Margin-3.0K%-511%Prev. FY
FAQs on Financials of Telluris Biotech
No. In FY25, Telluris Biotech reported a net loss of ₹6.9 Cr, so it was not profitable.
Telluris Biotech's revenue declined 82.0% year-on-year, from ₹1.3 Cr in FY24 to ₹23.3 Lakh in FY25.
Telluris Biotech's estimated EBITDA for FY25 was ₹-5.5 Cr, derived from its profit before tax, finance costs, and depreciation & amortisation.
In FY25, Telluris Biotech posted revenue of ₹23.3 Lakh (down 82.0% YoY) and a net loss of ₹6.9 Cr. Explore the full financials of Telluris Biotech here...
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links